@article{989f015560094c329da2c9185efec3be,
title = "TSLP elicits IL-33-independent innate lymphoid cell responses to promote skin inflammation.",
abstract = "Innate lymphoid cells (ILCs) are a recently identified family of heterogeneous immune cells that can be divided into three groups based on their differential developmental requirements and expression of effector cytokines. Among these, group 2 ILCs produce the type 2 cytokines interleukin-5 (IL-5) and IL-13 and promote type 2 inflammation in the lung and intestine. However, whether group 2 ILCs reside in the skin and contribute to skin inflammation has not been characterized. We identify a population of skin-resident group 2 ILCs present in healthy human skin that are enriched in lesional human skin from atopic dermatitis (AD) patients. Group 2 ILCs were also found in normal murine skin and were critical for the development of inflammation in a murine model of AD-like disease. Remarkably, in contrast to group 2 ILC responses in the intestine and lung, which are critically regulated by IL-33 and IL-25, group 2 ILC responses in the skin and skin-draining lymph nodes were independent of these canonical cytokines but were critically dependent on thymic stromal lymphopoietin (TSLP). Collectively, these results demonstrate an essential role for IL-33- and IL-25-independent group 2 ILCs in promoting skin inflammation.",
author = "Kim, {Brian S} and Siracusa, {Mark C} and Saenz, {Steven A} and Mario Noti and Monticelli, {Laurel A} and Sonnenberg, {Gregory F} and Hepworth, {Matthew R} and {Van Voorhees}, {Abby S} and Comeau, {Michael R} and David Artis",
note = "2-P30 CA016520, NCI NIH HHS, United States5-P30-AR-057217, NIAMS NIH HHS, United StatesAI061570, NIAID NIH HHS, United StatesAI074878, NIAID NIH HHS, United StatesAI083480, NIAID NIH HHS, United StatesAI085828, NIAID NIH HHS, United StatesAI087990, NIAID NIH HHS, United StatesAI095466, NIAID NIH HHS, United StatesAI095608, NIAID NIH HHS, United StatesAI097333, NIAID NIH HHS, United StatesAI102942, NIAID NIH HHS, United StatesDP5 OD012116, NIH HHS, United StatesDP5OD012116, NIH HHS, United StatesKL2 TR000139, NCATS NIH HHS, United StatesKL2-RR024132, NCRR NIH HHS, United StatesKL2TR000139, NCATS NIH HHS, United StatesP30 AR057217, NIAMS NIH HHS, United StatesP30 CA016520, NCI NIH HHS, United StatesP30-DK050306, NIDDK NIH HHS, United StatesR01 AI061570, NIAID NIH HHS, United StatesR01 AI074878, NIAID NIH HHS, United StatesR01 AI095466, NIAID NIH HHS, United StatesR01 AI097333, NIAID NIH HHS, United StatesR01 AI102942, NIAID NIH HHS, United StatesR21 AI083480, NIAID NIH HHS, United StatesR21 AI087990, NIAID NIH HHS, United StatesT32 AI007532, NIAID NIH HHS, United StatesT32-AI007532, NIAID NIH HHS, United StatesU01 AI095608, NIAID NIH HHS, United States",
year = "2013",
month = jan,
day = "30",
doi = "10.1126/scitranslmed.3005374",
language = "English",
volume = "5",
journal = "Science Translational Medicine",
issn = "1946-6234",
publisher = "American Association for the Advancement of Science (A A A S)",
number = "170",
}